Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

作者：Timothy P. Sheahan, Amy Sims, Rachel L. Graham, Vineet D. Menachery, Lisa E. Gralinski, James Brett Case, Sarah R. Leist, Krzysztof Pyrć, Joy Y. Feng, Iva Trantcheva, Roy Bannister, Yeojin Park, Darius Babusis, Michael O. Clarke, Richard L. Mackman, Jamie E. Spahn, Christopher A. Palmiotti, Dustin S. Siegel, Adrian S. Ray, Tomáš Cihlář, Robert Jordan, Mark R. Denison, Ralph S. Baric · 发表于：Science Translational Medicine · 年份：2017 · DOI：10.1126/scitranslmed.aal3653 · 被引用次数：1641 · 研究领域：SARS-CoV-2 and COVID-19 Research、Viral gastroenteritis research and epidemiology、Animal Virus Infections Studies

values. GS-5734 was also effective against bat CoVs, prepandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells, thus demonstrating broad-spectrum anti-CoV activity. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of GS-5734 significantly reduced lung viral load and improved clinical signs of disease as well as respiratory function. These data provide substantive evidence that GS-5734 may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.